These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 28569047

  • 1. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N.
    Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
    [Abstract] [Full Text] [Related]

  • 2. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators.
    Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
    [Abstract] [Full Text] [Related]

  • 3. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
    Deegan P, Khan A, Camelo JS, Batista JL, Weinreb N.
    Orphanet J Rare Dis; 2021 Feb 18; 16(1):92. PubMed ID: 33602299
    [Abstract] [Full Text] [Related]

  • 4. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
    Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C.
    J Inherit Metab Dis; 2013 May 18; 36(3):543-53. PubMed ID: 22976765
    [Abstract] [Full Text] [Related]

  • 5. Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Sevittz H, Laher F, Varughese ST, Nel M, McMaster A, Jacobson BF.
    S Afr Med J; 2022 Feb 02; 112(1):13518. PubMed ID: 35140000
    [Abstract] [Full Text] [Related]

  • 6. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Feb 02; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 7. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):66-72. PubMed ID: 21112800
    [Abstract] [Full Text] [Related]

  • 8. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
    Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ.
    Br J Haematol; 2009 Nov 15; 147(4):561-70. PubMed ID: 19732054
    [Abstract] [Full Text] [Related]

  • 9. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan 15; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 10. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.
    Mol Genet Metab; 2016 Feb 15; 117(2):164-71. PubMed ID: 26043810
    [Abstract] [Full Text] [Related]

  • 11. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
    Zimran A, Morris E, Mengel E, Kaplan P, Belmatoug N, Hughes DA, Malinova V, Heitner R, Sobreira E, Mrsić M, Granovsky-Grisaru S, Amato D, vom Dahl S.
    Blood Cells Mol Dis; 2009 Feb 15; 43(3):264-88. PubMed ID: 19502088
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
    Giraldo P, Irún P, Alfonso P, Dalmau J, Fernández-Galán MA, Figueredo A, Hernández-Rivas JM, Julia A, Luño E, Marín-Jimenez F, Martín-Nuñez G, Montserrat JL, de la Serna J, Vidaller A, Villalón L, Pocovi M.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):115-8. PubMed ID: 20934891
    [Abstract] [Full Text] [Related]

  • 13. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H, Kaplan P, Kacena K, Yee J.
    Pediatrics; 2008 Dec 15; 122(6):1182-90. PubMed ID: 19047232
    [Abstract] [Full Text] [Related]

  • 14. Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Cappellini MD, Carubbi F, Di Rocco M, Giona F, Giuffrida G.
    Blood Cells Mol Dis; 2023 Jan 15; 98():102705. PubMed ID: 36327675
    [Abstract] [Full Text] [Related]

  • 15. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 15; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 16. Enzyme replacement therapy with imiglucerase in a Taiwanese child with type 1 Gaucher disease.
    Lin HY, Lin SP, Chuang CK, Wraith JE.
    J Chin Med Assoc; 2006 May 15; 69(5):228-32. PubMed ID: 16835986
    [Abstract] [Full Text] [Related]

  • 17. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results.
    Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, Niederau C, Häussinger D, Mödder U.
    Skeletal Radiol; 2001 Sep 15; 30(9):496-503. PubMed ID: 11587517
    [Abstract] [Full Text] [Related]

  • 18. Retrospective Analysis of Whole-Body Magnetic Resonance Imaging of Bone Manifestations in Long-Term Treated Patients with Gaucher Disease Type 1.
    Lollert A, Laudemann K, Mengel E, Hoffmann C, Moos L, Reinke J, Brixius-Huth M, Hennermann JB, Düber C, Staatz G.
    Klin Padiatr; 2019 Mar 15; 231(2):52-59. PubMed ID: 30481833
    [Abstract] [Full Text] [Related]

  • 19. Management of Gaucher disease: enzyme replacement therapy.
    Zimran A, Elstein D.
    Pediatr Endocrinol Rev; 2014 Sep 15; 12 Suppl 1():82-7. PubMed ID: 25345089
    [Abstract] [Full Text] [Related]

  • 20. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J, Dulisse B, Grabowski GA, Weinreb NJ.
    Clin Genet; 2007 Mar 15; 71(3):205-11. PubMed ID: 17309642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.